A multicenter phase II open-label study in untreated patients with CD20 positive indolent B-cell non-Hodgkin's lymphoma evaluating efficacy and safety of maintenance therapy with IDEC-C2B8
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Dec 2009
At a glance
- Drugs Rituximab (Primary)
- Indications B cell lymphoma
- Focus Therapeutic Use
- Sponsors Zenyaku Kogyo
- 25 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 29 Dec 2008 New trial record.